arrow
P

Patrizia Mondello

Mayo Clinic
H指数:27
被引数:2,377

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenström macroglobulinemia

多组学分析揭示MYD88野生型华氏巨球蛋白血症中存在独特的表观遗传特征

2026-05-010
OA
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia

POD24是沃尔德斯特伦巨球蛋白血症患者预后的新型决定因素。

2026-01-090
OAAI
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts

滤泡性淋巴瘤3B亚型具有不同的预后结局:来自前瞻性多中心MER和LEO队列的研究结果

2025-08-080
OAAI
Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival

淋巴瘤患者接受CAR T疗法时出现的低镁血症与免疫功能紊乱和生存率降低相关。

2025-04-300
OA
Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype

PIM激酶的靶向在ABC亚型的弥漫性大b细胞淋巴瘤中显示出单一药物的功效,并与BCL2抑制剂协同作用

2025-03-010
PRE
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL
2024-06-202
OAAI
Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments
2024-03-015
OAAI
MicroRNA and long non-coding RNA analysis in IgM-monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis
2023-12-071
OAAI
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (vol 102, pg 1773, 2023)
2023-07-112
OAAI